Drug intelligence / Profile preview

TERT-201

Development stage: Preclinical
Lead developer: Rejuvenation Technologies
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

TERT-201 is an mRNA therapeutic developed by Rejuvenation Technologies. It aims to reverse aging by extending telomeres through the delivery of telomerase mRNA. The drug utilizes proprietary lipid nanoparticles (LNPs) to specifically deliver the telomerase mRNA to target tissues, such as the lung and liver. It is currently in preclinical development for fibrotic diseases, including pulmonary fibrosis and liver cirrhosis, with plans to advance towards IND approval. Early research also targets the immune system.

Targets

TERT (Telomerase)

Beyond the preview

Go deeper on TERT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TERT-201.

Explore the full profile